Ace Therapeutics helps clients identify biomarkers of susceptibility or risk for psychiatric disorders through our platform technology. These biomarkers may include genetic variants, protein expression patterns, metabolite levels, and more. Our one-stop biomarker discovery and validation service can help clients predict potential biomolecules that put individuals at risk of developing a psychiatric disorder, thereby guiding the precise diagnosis of psychiatric disorders and the development of personalized therapies.

Introduction of Susceptibility or Risk Biomarkers

Susceptibility or risk biomarkers are often used as indicators of risk for developing a disease or medical condition. A potential correlation between interleukin 6 (IL-6) and C-reactive protein (CRP) levels and the risk of developing SCZ has been demonstrated. Lower CRP levels and blockage of IL-6 signaling significantly increase the risk of SCZ and are considered potential susceptibility/risk biomarkers for this neuropsychiatric disorder. Thus, susceptibility or risk biomarkers can provide early warning before the onset of psychiatric symptoms, aiding in the development of early intervention and personalized prevention strategies.

Our Susceptibility or Risk Biomarker Development Services

Biomarker discovery and validation for psychiatric disorders is a complex and lengthy process, and Ace Therapeutics is working to achieve precision prevention of complex disorders by integrating information from multiple genetic susceptibility loci, as well as other potential biomarkers, thereby greatly improving the ability to predict, screen, and intervene in populations at high risk of psychiatric disorders prior to their onset.

The following are the key steps we consider in the development of biomarkers of susceptibility or risk for psychiatric disorders:

• Biomarker screening services

We combine multi-omics analytical techniques with high-throughput screening analyses to analyze biological samples to identify potential biomarkers associated with risk for psychiatric disorders.

• Biomarker validation and functional studies

We validated the potential biomarkers screened by in vitro and in vivo assays to determine their mechanisms of action in the development of psychiatric disorders.

• Personalized assessment tool development

Our professional data analysis services assess the predictive value and clinical application potential of biomarkers, thus providing valuable data for our clients' research.

Advantages of Our Susceptibility or Risk Biomarker Development Services

• Customized solutions to ensure research goals are met based on client demands.
• Our robust and analytically appropriate laboratory testing procedures guarantee the development of reliable risk biomarkers for our clients.
• Rigorous quality control processes are in place to guarantee the reliability and reproducibility of the final results.

Ace Therapeutics is committed to applying our expertise to help our clients advance in the research and development of biomarkers for susceptibility to psychiatric disorders. Please contact us for more details and we will be happy to assist you.